2nd European Clinical Trials Inspection Readiness Summit

The early phases of a clinical trial are the most crucial. This is where the potential of a drug is evaluated and applied to the treatment at stake. However, these phases are also the most expensive and regulated portions of a trial. It can cost up to two billion dollars just to complete the early phases of a clinical trial, and sometimes they are even bypassed. If this does not occur and a drug does go through phase I and phase IIA, corners can be proactively cut to decrease costs, meet regulatory requirements and ensure efficacy.

The 3rd Clinical Trials Phase I and Phase IIA Summit will explore paramount strategies behind increasing efficiency in early phase clinical trials. Join us May 12-13, 2016 to hear from top industry thought leaders and have the chance learn from the best. As the early clinical development space is continuously evolving, this must-attend event will feature countless case studies and networking opportunities to address current challenges.

Top Five Reasons to Attend

1. Learn best practices for early decision-making through analysis of biomarker utility in drug development
2. Use analytical technology to evaluate multiple configurations of a small molecule to increase the feasibility of Drug in Clinical Trials
3. Identify compound development strategies to optimize success in clinical trials
4. Implement adaptive design in proof of concept studies to increase efficiency, decrease time and decrease overall cost
5. Explore the seamless development of phase I to phase II in clinical trials